Status:
UNKNOWN
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
Lead Sponsor:
Instituto Brasileiro de Controle do Cancer
Conditions:
Chemotherapy-induced Nausea and Vomiting
Eligibility:
All Genders
18+ years
Brief Summary
Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or...
Detailed Description
The investigators will track patients in the first and second cycles of chemotherapy. Information regarding comorbidities, medical history and sociodemographic characteristics will be collected. The i...
Eligibility Criteria
Inclusion
- Patients with histological confirmation of cancer;
- Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis;
- No previous cancer treatment for the current diagnosis (excluding surgery);
Exclusion
- Patients who have an inability to answer the questionnaire, due to lack of discernment to answer the questions reliably;
- Patients who report vomiting during the 24 hours prior to the first cycle of chemotherapy treatment;
- Patients who have a disease or condition that could cause emesis (ie, metastasis in the central nervous system, gastrointestinal obstruction or metabolic and electrolyte imbalances);
- Patients using opioids or illicit drugs;
- Alcoholism;
Key Trial Info
Start Date :
August 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04785495
Start Date
August 12 2020
End Date
November 1 2021
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rafaela de Brito Alves
São Paulo, São Paulo, Brazil, 03102-002